SHA:601607 Revenue

In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B CNY with 5.75% growth. Shanghai Pharmaceuticals Holding had revenue of 65.62B in the quarter ending December 31, 2024, with 4.52% growth.

Revenue

275.25B

Revenue Growth

+5.75%

P/S Ratio

0.26

Revenue / Employee

5.71M

Employees

48,164

Market Cap

62.96B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	275.25B	14.96B	5.75%
Dec 31, 2023	260.30B	28.31B	12.21%
Dec 31, 2022	231.98B	16.16B	7.49%
Dec 31, 2021	215.82B	23.92B	12.46%
Dec 31, 2020	191.91B	5.34B	2.86%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Jiangsu Hengrui Medicine	27.98B
Shenzhen Mindray Bio-Medical Electronics	37.11B
WuXi AppTec	37.92B
Aier Eye Hospital Group	20.62B
Zhangzhou Pientzehuang Pharmaceutical.,	10.91B
Yunnan Baiyao Group Co.,Ltd	39.34B
Shanghai United Imaging Healthcare	10.30B
Sichuan Biokin Pharmaceutical	5.82B

Revenue Rankings

Shanghai Pharmaceuticals Holding News

3 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
3 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha

More News